

Antiarrhythmics & QT Prolongation: Avoiding Drug Interactions



MELINDA DEUBNER, PHARMD, BCCCP

**A webinar for HealthTrust members
August 24, 2018**



Disclosures



- The presenter has no real or perceived conflicts of interest related to this presentation
- This program contains the mention of suppliers, brands, products, services or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand, product, service or drug.

Learning Objectives



1. Describe the electrophysiology of the heart and the connection between different ion channels and the electrocardiogram.
2. Identify antiarrhythmic classes and their effects on the QT interval.
3. Manage interactions between antiarrhythmic medications and other drugs which may cause QT prolongation.

Drug Induced QT Prolongation



True prevalence difficult to assess

Arrhythmias typically fatal outside the hospital



Many patients exposed to QT-prolonging agents in ICU

Increased drastically in cardiovascular ICU




ICU patients at high risk for drug-drug interactions

18.6% of patients on >1 QT-prolonging drug had increased mortality


Cardiac Action Potential

Action potential of cardiac muscles

Grigoriy Ikonnikov and Eric Wong



Action Potential & the ECG



QT Prolongation



Caused by blocking of potassium efflux leading to delayed ventricular repolarization

Normal QT interval in is <440 msec* in men, <450 msec in women

Puts patient at risk for reentry arrhythmias, particularly Torsades de Pointes (TdP)


TdP is generally associated with a QT interval > 500 msec



Can lead to sudden cardiac death

Treatment:

- Direct cardioversion for episodes longer than 5 seconds
- Immediate defibrillation if pulseless
- Magnesium 2g slow IV push



Torsades de Pointes

Poll: Test Your Understanding



Which ion channels would need to be affected to cause QT prolongation?

- A. Sodium channels
- B. Potassium channels
- C. Calcium channels
- D. All of the above

RESULTS



Which ion channels would need to be affected to cause QT prolongation?

A. Sodium channels

B. Potassium channels

C. Calcium channels

D. All of the above








Antiarrhythmic Drug Actions

Antagonist relative potency:

- L = Low
- M = Moderate
- H = High

ACh = Acetylcholine

Ado = Adenosine

Vaughn-Williams Class	DRUG	ECG Changes	CHANNELS			RECEPTORS			
			Ca ⁺⁺	Na ⁺	K ⁺	α	β	ACh	Ado
A	Quinidine	 A		M	M	L		M	
	Procainamide			M	M				
	Disopyramide			M	M			M	
I B	Lidocaine	 B		L					
	Mexiletine			L					
C	Propafenone	 C		H				M	
	Flecainide			H					
II	β-Adrenergic antagonists							H	
III	Dronedarone		L	L	H	M	M	M	
	Amiodarone		L	L	H	M	M	M	
	Sotalol				H		H		
	Ibutilide			△	H				
	Dofetilide				H				
IV	Verapamil Diltiazem		M M						
Misc	Adenosine								△

△ = Agonist

● = ECG Changes related to Ca⁺⁺ channel block

● = ECG Changes related to Na⁺ channel block

● = ECG Changes related to K⁺ channel block

Class Ia Antiarrhythmics



Agents: Quinidine, Procainamide, Disopyramide

Mechanism of Action

- Moderately blocks sodium influx and potassium efflux

Indication

- Atrial fibrillation and flutter
- Ventricular and supraventricular tachyarrhythmias

Arrhythmia

- Prolonged QT interval
- May cause Torsades de Pointes

Class Ia Antiarrhythmics



	Quinidine	Procainamide
Usual Dose Range	200-600mg PO Q 6-12 hours	Max total IV dose of 100mg (as boluses or infusion)
Kinetics	Metabolized by CYP3A4	Metabolized by CYP2D6
Risk of QT Prolongation	High	Moderate

Class Ib Antiarrhythmics



Agents: Lidocaine, Mexilitine

Mechanism of Action

- Weakly blocks sodium channels

Indication

- Ventricular arrhythmias

Arrhythmia

- Not associated with negative effects on cardiac rhythm
- Shorten QT interval

Class Ib Antiarrhythmics



	Lidocaine	Mexilitine
Usual Dose Range	1-1.5mg/kg IV bolus, with max cumulative dose of 3mg/kg	150-300 mg PO Q 8-12 hours
Kinetics	Metabolized by CYP3A4	Metabolized by CYP2D6
Risk of QT Prolongation	None	None

Class Ic Antiarrhythmics



Agents: Propafenone, Flecainide

Mechanism of Action

- Highly blocks sodium influx

Indication

- Ventricular and supraventricular tachyarrhythmias

Arrhythmia

- Can prolong QT
- Ischemia predisposes patients to reentry tachyarrhythmias
- Avoid in patients with CAD

Class Ic Antiarrhythmics



	Propafenone	Flecainide
Usual Dose Range	150-300mg PO Q 8 hours	50-200mg PO Q 12 hours
Kinetics	Metabolized by CYP2D6	Metabolized by CYP2D6
Risk of QT Prolongation	Low Risk (higher in patients with CAD)	Low Risk (higher in patients with CAD)

Class II Antiarrhythmics



Agents: Metoprolol, Labetalol, Esmolol, etc.

Mechanism of Action

- Blocks beta adrenergic receptors

Indication

- Hypertension, angina, MI, heart failure (varies by agent)

Arrhythmia

- Low risk
- May cause some AV block

Class II Antiarrhythmics



	Metoprolol	Labetalol	Esmolol
Usual Dose Range	25-200mg PO Q 12-24 hours	10-80mg IV Q 20 min (max 300mg/day)	500-1000mcg/kg IV bolus, then 50- 300 mcg/kg/min
Kinetics	Metabolized by CYP2D6	Metabolized by glucuronide conjugation	Metabolized by red blood cell esterases
Risk of QT Prolongation	None	None	None

Sources: Smithburger PL et al. Expert Opin Drug Saf. 2010 Sep;9(5):699-712.

Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; 2018; July 17, 2018.

Class III Antiarrhythmics



Agents: Amiodarone, Dofetilide, Sotalol, Dronedarone, etc.

Mechanism of Action

- Highly block potassium channels
- Can also have effects on Na and Ca channels as well as adrenergic receptors

Indication

- Atrial and ventricular tachyarrhythmias

Arrhythmia

- Low to high risk depending on agent
- QT prolongation
- May cause Torsades de Pointes

Class III Antiarrhythmics



	Amiodarone	Dofetilide	Sotalol
Usual Dose Range	200-400mg PO Q 8-24 hours	250-500mcg PO Q 12 hours	80-160mg PO Q 12 hours
Kinetics	Metabolized by CYP3A4 and CYP2C8	Metabolized by CYP3A4	Excreted in urine as unchanged drug
Risk of QT Prolongation	Low	High	High

Class IV Antiarrhythmics



Agents: Verapamil, Diltiazem

Mechanism of Action

- Moderately blocks calcium channels

Indication

- Atrial fibrillation, supraventricular tachycardias, hypertension, angina

Arrhythmia

- Low risk
- May cause some AV block

Class IV Antiarrhythmics



	Verapamil	Diltiazem
Usual Dose Range	80-160mg PO Q 8 hours	15-20mg IV, then 5-15 mg/hour
Kinetics	Metabolized by CYP3A4	Metabolized by CYP3A4
Risk of QT Prolongation	None	None

Antiarrhythmics and QT Prolongation



May Prolong QT

- Class Ic
(Propafenone,
Flecainide)

Associated with TdP

- Class Ia (Quinidine,
Procainamide,
Disopyramide)
- Class III
(Amiodarone,
Dofetilide, Sotalol,
Dronedarone,
Ibutilide)

Other Risk Factors for Drug-induced Arrhythmias



Preexisting
cardiac disease

Shock and
vasopressor use

Organ failure and
impaired kinetics

Electrolyte
imbalances


Drug-drug
interactions

Electrolyte Imbalances



Hypo/Hyperkalemia

Hypomagnesemia



Hypocalcemia

Poll: Test Your Understanding



Which one of these drugs could cause an arrhythmia through electrolyte disturbances?

- A. Nitrofurantoin
- B. Acetaminophen
- C. Ceftriaxone
- D. Albuterol

RESULTS



Which one of these drugs could cause an arrhythmia through electrolyte disturbances?

- A. Nitrofurantoin
- B. Acetaminophen
- C. Ceftriaxone
- D. Albuterol

Drugs Causing Electrolyte Imbalances



• Hypokalemia

- Beta agonists
- Catecholamines
- Insulin
- Diuretics (loop and thiazide)
- Aminoglycosides
- Amphotericin B
- Steroids

• Hypomagnesemia

- Diuretics (loop and thiazide)
- Aminoglycosides
- Amphotericin B
- Cisplatin
- Cyclosporine
- Digoxin
- Mannitol
- Methotrexate
- Citrate-containing products
- Laxatives

• Hyperkalemia

- Potassium-sparing diuretics
- ACE inhibitors
- NSAIDs
- Succinylcholine
- Beta antagonists
- Digoxin
- SMX/TMP

Drug-Drug Interactions Causing QT Prolongation



CNS

Methadone

Antipsychotics

Antidepressants

Drug-Drug Interactions Causing QT Prolongation



CNS

Methadone
Antipsychotics
Antidepressants

Antimicrobial

Macrolides
Fluoroquinolones
Azole Antifungals

Drug-Drug Interactions Causing QT Prolongation



CNS

Methadone
Antipsychotics
Antidepressants

Antimicrobial

Macrolides
Fluoroquinolones
Azole Antifungals

Gastrointestinal

Antiemetics
Proton Pump Inhibitors

Anesthetics/Analgesics



Volatile anesthetics: sevoflurane, halothane,
isoflurane, enflurane

Methadone – QT prolonging

Fentanyl and Morphine – Not QT prolonging

Methadone



Indications: Chronic pain and opioid addiction

Usual dose range: 20 to 120mg

Kinetics: Levels increased by CYP 3A4 inhibitors, Cleared renally

Antipsychotics



Most problematic agents:
Haloperidol, Droperidol, Thioridazine

Causing QT prolongation but rarely >500 msec:
Ziprasidone, Quetiapine, Olanzapine, Risperidone

Haloperidol



Indications: Behavioral and psychotic disorders, schizophrenia, hyperactivity

Usual dose range: 0.5 to 100mg IV or PO, doses >35mg/day increase risk of QT prolongation

Kinetics: Levels increased by CYP 3A4 inhibitors

Antidepressants



Selective Serotonin Reuptake Inhibitors

More concerning when used in combination with
other QT prolonging agents

SSRI



Indications: Generalized anxiety disorder, major depressive disorder, etc.

Commonly used agents: Citalopram, Escitalopram, Fluoxetine

Kinetics: Levels increased by CYP 3A4 inhibitors

Macrolides



Azithromycin – Commonly used inpatient and outpatient antibiotic

Clarithromycin

Erythromycin – Commonly used as promotility agent

Azithromycin



Indications: Community-acquired pneumonia, COPD exacerbations, etc.

Usual dose range: 250-500mg IV/PO daily

Kinetics: Levels increased by CYP3A4 inhibitors

Fluoroquinolones



Levofloxacin, Moxifloxacin, Ciprofloxacin

Levofloxacin



Indications: Community-acquired pneumonia

Usual dose range: 250-750mg IV/PO Q 24-48 hours

Kinetics: Mostly excreted as unchanged drug in the urine, minimal CYP metabolism

Azole Antifungals



Fluconazole, Itraconazole, Ketoconazole,
Voriconazole

More concerning when used in combination with
other QT prolonging agents, especially those
requiring metabolism by CYP 3A4

Fluconazole



Indications: Treatment of yeast infections, including candidiasis

Usual dose range: 200-800mg PO/IV Q 24 hours

Kinetics: Moderate inhibitor of CYP_{3A4}, CYP_{2c9}, Strong inhibitor of CYP_{2C19}

Voriconazole



Indications: Treatment of yeast and mold infections, including aspergillus

Usual dose range: 4-6mg/kg IV Q 12 hours; 100-400mg PO Q 12 hours

Kinetics: Strong CYP3A4 inhibitor, moderate CYP2C19 inhibitor, weak CYP2C9 inhibitor

Antiemetics



High Risk for TdP: Droperidol, Chlorpromazine

Lower Risk: Ondansetron, Dolasetron

Ondansetron



Indications: Post-operative, chemo/radiation-induced nausea and vomiting

Usual dose range: 4-8mg Q 8-12 hours (doses >16mg not recommended)

Kinetics: Levels increased by CYP3A4 inhibitors

Promotility Agent



Erythromycin – macrolide antibiotic
which binds motilin receptors in
GI tract causing increased motility

Erythromycin



Indications: Bacterial infections,
Gastroparesis (off-label)

Usual dose range: 250-500 mg IV/PO Q
6-12 hours


Kinetics: More risk of TdP with IV
administration; Levels increased by
CYP3A4 inhibitors

Preventative Strategies for Drug Interactions



Awareness
of risk
factors


Preventative Strategies for Drug Interactions



Preventative Strategies for Drug Interactions, *continued*



Preventative Strategies for Drug Interactions, *continued*




Preventative Strategies for Drug Interactions, *continued*



Daily review of
the patient's
medication
profile

Preventative Strategies for Drug Interactions, *continued*



Metabolic Interactions of QT Prolonging Agents



Metabolic Interactions of QT Prolonging Agents



Level increased by
CYP3A4 Inhibitors:

Quinidine
Amiodarone
Methadone
Haloperidol
SSRIs
Azithromycin
Erythromycin
Ondansetron

Strong CYP3A4
Inhibitors

Metabolic Interactions of QT Prolonging Agents




Level increased by
CYP3A4 Inhibitors:

Quinidine
Amiodarone
Methadone
Haloperidol
SSRIs
Azithromycin
Erythromycin
Ondansetron


Strong CYP3A4
Inhibitors:

Clarithromycin
Cobicistat
Itraconazole
Ketoconazole
Posaconazole
Telithromycin
Voriconazole
Protease inhibitors

Metabolic Interactions of QT Prolonging Agents, *continued*



Metabolic Interactions of QT Prolonging Agents, *continued*



Metabolic Interactions of QT Prolonging Agents, *continued*



Level increased by
CYP2D6 Inhibitors:

Procainamide

Propafenone

Flecainide

Strong
CYP2D6 Inhibitors:

Bupropion

Fluoxetine

Paroxetine

Quinidine

Tipranavir

Poll: Test Your Understanding



You are reviewing the chart of a patient being treated for opioid addiction with methadone. Which concurrent medication raises your concern for a drug interaction that could lead to an increased risk of QT prolongation?

- A. Famotidine
- B. Losartan
- C. Boceprevir
- D. Gabapentin

RESULTS



You are reviewing the chart of a patient being treated for opioid addiction with methadone. Which concurrent medication raises your concern for a drug interaction that could lead to an increased risk of QT prolongation?

A. Famotidine

B. Losartan

C. Boceprevir

D. Gabapentin

Poll: Test Your Understanding



In the previous patient being treated with both boceprevir and methadone, what monitoring would you recommend to prevent serious morbidity?

- A. Daily chemistries including potassium and magnesium levels
- B. Frequent ECG while the dose of methadone is being titrated
- C. Monitoring for additional QT prolonging agents through daily chart review
- D. Renal function monitoring through daily serum creatinine measurement

RESULTS



In the previous patient being treated with both boceprevir and methadone, what monitoring would you recommend to prevent serious morbidity?

- A. Daily chemistries including potassium and magnesium levels
- B. Frequent ECG while the dose of methadone is being titrated
- C. Monitoring for additional QT prolonging agents through daily chart review
- D. Renal function monitoring through daily serum creatinine measurement

Information Resource:

<https://crediblemeds.org/healthcare-providers/>

CredibleMeds[®]

A Trusted Partner Providing Reliable Information On Medicines

CredibleMeds Mobile Apps Available Now!

Available for Apple IOS, Android and Windows Mobile devices

Convenient mobile access to the QTdrugs database for healthcare providers and patients

Instant access to latest revisions to the QTdrugs lists

FOR EVERYONE **FOR HEALTHCARE PROVIDERS** **FOR RESEARCH SCIENTISTS**

CredibleMeds > For Healthcare Providers

Print Share RSS Donate

Search terms Search

Members Login Register Here

PAGES FOR HEALTHCARE PROVIDERS

- QTDrugs Lists (registration required)
- Clinical Factors Associated with Prolonged QTc and/or TdP
- CredibleRx™ Rx Tools - Flockhart's Table

Resources for Healthcare Professionals



This section of CredibleMeds® includes tools to assist physicians, nurses, pharmacists and other healthcare professionals who play central roles in medication safety.

QT Drugs Lists: This portal includes [QTdrugs.org](https://www.qtdrugs.org/), a list of drugs categorized by their potential to cause QT prolongation and/or torsades de pointes (TdP). Click on a drug and see if the FDA-approved label recommends ECG monitoring.

QTFactors.org - Clinical Factors Associated with Prolonged QTc and/or TdP: This is a list of clinical factors that have been associated in the medical literature with prolonged QTc and/or Torsades de Pointes (TdP).

Information Resource:

<https://crediblemeds.org/healthcare-providers/>

X	
Generic Name(s)	Quetiapine
Brand Names (Partial List)	Seroquel
Current TdP risk category	 Drugs with conditional TdP risk  Drugs to be avoided by congenital Long QT
Conditions for TdP if Conditional Risk Drug	Bradycardia, Low serum K or Mg, Excessive dose, Impaired drug elimination, Use with concomitant QT/TdP drug
Main Therapeutic Use(s)	Schizophrenia
Route(s) administered	oral
Market Status	On US and non US Market
Drug Label	<input checked="" type="checkbox"/> QT increase mentioned <input checked="" type="checkbox"/> Monitor QT in certain patients (Overdose)

Poll: Test Your Understanding



You are reviewing the chart of a 49-year old female patient with no allergies, who was admitted for community-acquired pneumonia. She has been started on levofloxacin and you note that she is also taking her home medication of quetiapine. Upon researching the QT prolongation risk of quetiapine you decide to intervene to prevent morbidity in this patient. What course of action do you decide to recommend?

- A. Discontinue levofloxacin and treat instead with azithromycin and ceftriaxone
- B. Discontinue quetiapine during this patient's inpatient stay
- C. Monitor the ECG daily and transfer the patient to a telemetry monitoring unit
- D. Discontinue the levofloxacin and treat instead with doxycycline

RESULTS



You are reviewing the chart of a 49 year old female patient with no allergies, who was admitted for community-acquired pneumonia. She has been started on levofloxacin and you note that she is also taking her home medication of quetiapine. Upon researching the QT prolongation risk of quetiapine you decide to intervene to prevent morbidity in this patient. What course of action do you decide to recommend?

- A. Discontinue levofloxacin and treat instead with azithromycin and ceftriaxone
- B. Discontinue quetiapine during this patient's inpatient stay
- C. Monitor the ECG daily and transfer the patient to a telemetry monitoring unit
- D. Discontinue the levofloxacin and treat instead with doxycycline

References



1. Barnes BJ, Hollands JM. Drug-induced arrhythmias. Crit Care Med. 2010 Jun;38(6 Suppl):S188-97.
2. Smithburger PL, Seybert AL, Armahizer MJ, et. al. QT prolongation in the intensive care unit: commonly used medications and the impact of drug–drug interactions. Expert Opin Drug Saf. 2010 Sep;9(5):699-712.
3. Ikonnikov G and Yelle D. Physiology of cardiac conduction and contractility. McMaster Pathophysiology Review. <http://www.pathophys.org/physiology-of-cardiac-conduction-and-contractility/>. Accessed July 27, 2018.
4. Woosley RL, Heise CW and Romero KA. CredibleMeds. QTdrugs List. <https://crediblemeds.org/new-drug-list/>. Accessed May 23, 2018.
5. Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.; 2018; July 17, 2018.

Antiarrhythmics and QT Prolongation: Avoiding Drug Interactions



THANK YOU
for attending today's webinar.

If you have further questions,
Melinda Deubner can be reached via email at:
mdeubner@beaconhealthsystem.org